Cogent Biosciences Inc
COGTHealthcare|Biotechnology|USA
$38.87
-1.62 (-4.00%)
Tangible Book
$3.18
Earnings Power
$4.21
Clinical Trials (17)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05208047 (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors | Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer | P3 | Recruiting | 482 | RCT, Open-label | CGT9486, CGT9486, Sunitinib, Sunitinib, Midazolam, CGT9486, Sunitinib, CGT9486, Sunitinib |
| NCT05186753 (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis | SSM, Mastocytosis, Indolent | P2 | Active | 237 | RCT, Double-blind | Bezuclastinib Tablets (Formulation A), Bezuclastinib Tablets (Formulation B), Placebo Tablets |
| NCT04996875 (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis | Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN) | P2 | Recruiting | 140 | Open-label | bezuclastinib |
| NCT06208748 SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST | Gastrointestinal Stromal Tumors, GIST | P2 | Active | 40 | Open-label | Bezuclastinib in combination with sunitinib |
| NCT06777316 A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors | Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma | P1P2 | Active | 110 | Open-label | CGT4859 |
| NCT07383506 A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors | PIK3CA Mutations, Advanced Solid Tumors, Adult | P1 | Recruiting | 90 | Open-label | CGT6297 |
| NCT07361562 A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors | Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer | P1 | Recruiting | 100 | Open-label | CGT4255 |
| NCT05041530 Abdominal Wall Closure After Laparotomy in Oncologic Surgery | Laparotomy | N/A | Recruiting | 30 | Open-label | — |
| NCT02401815 CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors | Gastrointestinal Stromal Tumors | P1P2 | Completed | 51 | Open-label | CGT9486, Pexidartinib, Sunitinib |
| NCT03266692 Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma, Multiple Myeloma in Relapse | P1 | Terminated | 15 | Open-label | ACTR087, SEA-BCMA |
| NCT02776813 Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma | Lymphoma | P1 | Completed | 34 | Open-label | ACTR087, rituximab |
| NCT03189836 Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma | Lymphoma | P1 | Terminated | 26 | Open-label | ACTR707, rituximab |
| NCT03680560 Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers | Solid Tumor, HER-2 Protein Overexpression | P1 | Terminated | 6 | Open-label | ACTR T Cell Product, Trastuzumab |
| NCT02840110 Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product | B Cell Lymphomas, Multiple Myeloma | Terminated | 22 | — | — | |
| NCT06915766 Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis | Systemic Mastocytoses, Indolent, Systemic Mastocytoses, Aggressive | AVAILABLE | — | — | Bezuclastinib | |
| NCT06948955 Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors | Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors | AVAILABLE | — | — | Bezuclastinib, Sunitinib | |
| NCT05687942 The REBUILD Trial: Closure of the Abdominal Wall | Surgical Incision | N/A | Unknown | 40 | Open-label | — |